From TCSDaily: "The Battle Over Drug Safety and Preemption: Coming Soon to a Congress Near You"
(Feb. 02, 2009). Excerpt:
The medical community knows this, and devotes considerable resources to tracking post-release experience with drugs to get feedback on any problems. Patients need to accept that using a new drug has risks and that is an unavoidable part of the price that must be paid if there are to be any drugs at all.
Perhaps there should be a fund for people harmed by such effects, paid for as part of the system, but drug makers should not be accused of negligence for a problem that is not a failure of evaluation procedures but a law of nature and statistics. The litigation approach introduces confusion that is moral as well as economic.